BroadOak Capital Partners is a privately held investment bank with a comprehensive focus on the life sciences industry. We offer advisory services including mergers and acquisitions, divestitures, business combinations, joint ventures, valuations and fairness opinions. We also engage in principal investment activities, including co-investments, as particularly compelling opportunities arise. Our sector focus includes research tools and consumables, diagnostics, therapeutics, healthcare IT, pharmaceutical services and medical devices.
BroadOak provides multinational corporations, middle-market and entrepreneurial clients with the customized attention of a boutique while delivering a range of expertise more typically associated with a larger firm. Our industry focus allows the firm’s principals to target their investment banking experience and insight to specific client needs.
BroadOak provides multinational corporations, middle-market and entrepreneurial clients with the customized attention of a boutique while delivering a range of expertise more typically associated with a larger firm. Our industry focus allows the firm’s principals to target their investment banking experience and insight to specific client needs.
Location: United States, California, Brisbane
Employees: 11-50
Founded date: 2006
Mentions in press and media 11
| Date | Title | Description |
| 14.11.2025 | BroadOak Capital Partners Announces New Investments Across Life Sciences Portfolio | BroadOak Capital Partners has announced a series of new growth investments that expand its life sciences platform and reinforce its position as a long-term partner to emerging industry leaders. The activity includes the first investment fro... |
| 29.10.2025 | BroadOak Capital Partners Adds $200 Million In Permanent Capital | BroadOak Capital Partners, a life sciences-focused investment and advisory firm, has secured more than $200 million in permanent capital, expanding its capacity to invest flexibly across the life sciences ecosystem. The new capital strength... |
| 16.10.2025 | Codis Receives Growth Capital | Codis, a St. Louis, Missouri-based CDMO focused on commercial spray drying, amorphous solid dispersions (ASD), particle engineering, and finished-dose manufacturing, received a growth investment from 1315 Capital, with participation from ex... |
| 22.08.2025 | KROMATID: $8 Million Series C Raised For Genomic Structural Analysis | KROMATID, a pioneering force in next-generation genomic structural analysis, announced the completion of its Series C funding round, which has raised a total of $8 million, significantly exceeding its initial capital goals. The latest tranc... |
| 28.07.2025 | Pluristyx Closes Investment Round | Pluristyx, a Seattle, WA-based provider of induced pluripotent stem cell (iPSC) technologies and proprietary gene editing solutions, closed its funding. The amount of the deal was not disclosed. The round was led by BioLife Solutions and Br... |
| 06.01.2025 | PBS Biotech: $17 Million In Growth Capital Raised | PBS Biotech – a provider of single-use bioreactor systems and bioprocess development services – announced it secured $17 million in follow-on growth capital from Avego Management and BroadOak Capital Partners. These funds will advance PBS’ ... |
| 22.06.2022 | Kemp Proteins Secures $5M Growth Financing from BroadOak Capital Partners | "Broadoak’s growth investment will enable us to acquire several S.I.P. fermenters, digitized controllers with off-site monitoring capabilities and additional lab space." - Michael Keefe, CEO Kemp Proteins FREDERICK, Md. (PRWEB) Ju... |
| 03.11.2021 | Interpace Biosciences Announces New $8 Million Term Loan with BroadOak Capital Partners and Repayment of Private Equity Loans - Form 8-K | Interpace Biosciences Announces New $8 Million Term Loan with BroadOak Capital Partners and Repayment of Private Equity Loans PARSIPPANY, NJ, November 2, 2021 (GLOBE NEWSWIRE) - Interpace Biosciences, Inc. ("Interpace" or the &quo... |
| 02.11.2021 | Interpace Biosciences Announces New $8 Million Term Loan with BroadOak Capital Partners and Repayment of Private Equity Loans | PARSIPPANY, NJ, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it, along with its subsidiaries, has entered into a new $8 million term loan with BroadOak Fund ... |
| 02.11.2021 | Interpace Biosciences Announces New $8 Million Term Loan with BroadOak Capital Partners and Repayment of Private Equity Loans | PARSIPPANY, NJ, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it, along with its subsidiaries, has entered into a new $8 million term loan with BroadOak Fund ... |
Show more